Evidence map›Paper›PMID 36271492›Full record

ArticleLife science alliance2022

The human RNA polymerase I structure reveals an HMG-like docking domain specific to metazoans.

Julia L Daiß, Michael Pilsl, Kristina Straub, Andrea Bleckmann, Mona Höcherl, Florian B Heiss, Guillermo Abascal-Palacios, Ewan P Ramsay, Katarina Tlučková, Jean-Clement Mars and 9 more

Abstract read
In one paragraph

Article in Life science alliance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. RiboScreenBiomedicines · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Julia L DaißRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.
Michael PilslRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.
Kristina StraubRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.
Andrea BleckmannRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.ORCID 0000-0002-0863-9840
Mona HöcherlRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.
Florian B HeissRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.ORCID 0000-0002-3934-1131
Guillermo Abascal-PalaciosDivision of Structural Biology, The Institute of Cancer Research, London, UK.ORCID 0000-0002-6805-5927
Ewan P RamsayDivision of Structural Biology, The Institute of Cancer Research, London, UK.
Katarina TlučkováInstitute of Science and Technology, Klosterneuburg, Austria.
Jean-Clement MarsDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Laval University, Quebec, Canada.
Torben FürtgesProtein Crystallography, Department of Biophysics, Faculty of Biology and Biotechnology, Ruhr University Bochum, Bochum, Germany.
Astrid BruckmannRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany.ORCID 0000-0001-6082-2944
Till RudackProtein Crystallography, Department of Biophysics, Faculty of Biology and Biotechnology, Ruhr University Bochum, Bochum, Germany.
Carrie BerneckyInstitute of Science and Technology, Klosterneuburg, Austria.
Valérie LamourUniversité de Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Department of Integrated Structural Biology, Illkirch, France.
Konstantin PanovSchool of Biological Sciences and PGJCCR, Queen's University Belfast, Belfast, UK.ORCID 0000-0003-1375-7814
Alessandro VanniniDivision of Structural Biology, The Institute of Cancer Research, London, UK.
Tom MossDepartment of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Laval University, Quebec, Canada.ORCID 0000-0003-2047-4783
Christoph EngelRegensburg Center for Biochemistry, University of Regensburg, Regensburg, Germany christoph.engel@ur.de.ORCID 0000-0001-8451-3599

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Transcription of the ribosomal RNA precursor by RNA polymerase (Pol) I is a major determinant of cellular growth, and dysregulation is observed in many cancer types. Here, we present the purification of human Pol I from cells carrying a genomic GFP fusion on the largest subunit allowing the structural and functional analysis of the enzyme across species. In contrast to yeast, human Pol I carries a single-subunit stalk, and in vitro transcription indicates a reduced proofreading activity. Determination of the human Pol I cryo-EM reconstruction in a close-to-native state rationalizes the effects of disease-associated mutations and uncovers an additional domain that is built into the sequence of Pol I subunit RPA1. This "dock II" domain resembles a truncated HMG box incapable of DNA binding which may serve as a downstream transcription factor-binding platform in metazoans. Biochemical analysis, in situ modelling, and ChIP data indicate that Topoisomerase 2a can be recruited to Pol I via the domain and cooperates with the HMG box domain-containing factor UBF. These adaptations of the metazoan Pol I transcription system may allow efficient release of positive DNA supercoils accumulating downstream of the transcription bubble.

Indexed as

RNA Polymerase IRNA PrecursorsAnimalsDNAHumansSaccharomyces cerevisiaeTranscription FactorsDNARNA Polymerase IRNA PrecursorsTranscription Factors

Identifiers

PMID36271492
PMCPMC9438803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.